Literature DB >> 15534911

The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines.

Sven Eisold1, Michael Linnebacher, Eduard Ryschich, Dalibor Antolovic, Ulf Hinz, Ernst Klar, Jan Schmidt.   

Abstract

AIM: There are conflicting data about p53 function on cellular sensitivity to the cytotoxic action of 5-fluorouracil (5-FU). Therefore the objective of this study was to determine the combined effects of adenovirus-mediated wild-type (wt) p53 gene transfer and 5-FU chemotherapy on pancreatic cancer cells with different p53 gene status.
METHODS: Human pancreatic cancer cell lines Capan-1(p53mut), Capan-2(p53wt), FAMPAC(p53mut), PANC1(p53mut), and rat pancreatic cancer cell lines AS(p53wt) and DSL6A(p53null) were used for in vitro studies. Following infection with different ratios of Ad-p53-particles (MOI) in combination with 5-FU, proliferation of tumor cells and apoptosis were quantified by cell proliferation assay (WST-1) and FACS (PI-staining). In addition, DSL6A syngeneic pancreatic tumor cells were inoculated subcutaneously in to Lewis rats for in vivo studies. Tumor size, apoptosis (TUNEL) and survival were determined.
RESULTS: Ad-p53 gene transfer combined with 5-FU significantly inhibited tumor cell proliferation and substantially enhanced apoptosis in all four cell lines with an alteration in the p53 gene compared to those two cell lines containing wt-p53. In vivo experiments showed the most effective tumor regression in animals treated with Ad-p53 plus 5-FU. Both in vitro and in vivo analyses revealed that a sublethal dose of Ad-p53 augmented the apoptotic response induced by 5-FU.
CONCLUSION: Our results suggest that Ad-p53 may synergistically enhance 5-FU-chemosensitivity most strikingly in pancreatic cancer cells lacking p53 function. These findings illustrate that the anticancer efficacy of this combination treatment is dependent on the p53 gene status of the target tumor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534911      PMCID: PMC4611997          DOI: 10.3748/wjg.v10.i24.3583

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells.

Authors:  M Kusumoto; T Ogawa; K Mizumoto; H Ueno; H Niiyama; N Sato; M Nakamura; M Tanaka
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

2.  Rare mutations of p53, Ki-ras, and beta-catenin genes and absence of K-sam and c-erbB-2 amplification in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat stomach cancers.

Authors:  Y Hirayama; K Wakazono; M Yamamoto; M Kitano; M Tatematsu; M Nagao; T Sugimura; T Ushijima
Journal:  Mol Carcinog       Date:  1999-05       Impact factor: 4.784

3.  Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.

Authors:  P Ghaneh; W Greenhalf; M Humphreys; D Wilson; L Zumstein; N R Lemoine; J P Neoptolemos
Journal:  Gene Ther       Date:  2001-02       Impact factor: 5.250

4.  Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer.

Authors:  Y Sasaki; I Morimoto; S Ishida; T Yamashita; K Imai; T Tokino
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

5.  Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.

Authors:  Meraj Mohiuddin; Damodaran Chendil; Swatee Dey; Rachael A Alcock; William Regine; Mohammed Mohiuddin; Mansoor M Ahmed
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

6.  In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug.

Authors:  M V Blagosklonny; W S el-Deiry
Journal:  Int J Cancer       Date:  1996-07-29       Impact factor: 7.396

7.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.

Authors:  Frederick F Lang; Janet M Bruner; Gregory N Fuller; Kenneth Aldape; Michael D Prados; Susan Chang; Mitchel S Berger; Michael W McDermott; Sandeep M Kunwar; Larry R Junck; William Chandler; James A Zwiebel; Richard S Kaplan; W K Alfred Yung
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

Review 8.  p53 gene therapy for esophageal cancer.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Takenori Ochiai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

9.  Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background.

Authors:  Sven Eisold; Eduard Ryschich; Michael Linnebacher; Thomas Giese; Dirk Nauheimer; Anja Wild; Detlef K Bartsch; Markus W Büchler; Jan Schmidt
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

10.  p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.

Authors:  D G Brachman; M Beckett; D Graves; D Haraf; E Vokes; R R Weichselbaum
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

View more
  7 in total

1.  Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes.

Authors:  Nathan P Gomes; Joaquín M Espinosa
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

2.  Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; A Aboukameel; Zhiwei Wang; Sanjeev Banerjee; Syed F Zafar; Anton-Scott Goustin; K Almhanna; Dajun Yang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Curr Cancer Drug Targets       Date:  2010-05       Impact factor: 3.428

Review 3.  Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors:  Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

4.  Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines.

Authors:  Ivana Grivicich; Andréa Regner; Caroline Zanoni; Larissa Procópio Correa; Geraldo Pereira Jotz; João Antônio Pêgas Henriques; Gilberto Schwartsmann; Adriana Brondani da Rocha
Journal:  Int J Colorectal Dis       Date:  2007-03-28       Impact factor: 2.571

5.  Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis.

Authors:  Silvia Alonso-de Castro; Alessio Terenzi; Sonja Hager; Bernhard Englinger; Adriana Faraone; Javier Calvo Martínez; Mathea Sophia Galanski; Bernhard K Keppler; Walter Berger; Luca Salassa
Journal:  Sci Rep       Date:  2018-11-21       Impact factor: 4.996

6.  Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Authors:  Guangyu Ma; Hideaki Shimada; Kenzo Hiroshima; Yuji Tada; Nobuo Suzuki; Masatoshi Tagawa
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

7.  Proton-shuttling lichen compound usnic acid affects mitochondrial and lysosomal function in cancer cells.

Authors:  Margret Bessadottir; Mar Egilsson; Eydis Einarsdottir; Iris H Magnusdottir; Margret H Ogmundsdottir; Sesselja Omarsdottir; Helga M Ogmundsdottir
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.